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SUMMARY
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This review focuses on the era of antibiosis that led to a better understanding of bacterial
morphology, in particlar the cell wall component peptidoglycan. This is an effort to take readers
on a tour de force from the concept of antibiosis, to the serepidity of antibiotics, evolution of betalactam development, and the molecular biology of antibiotic resistance. These areas of research
have culminated in a deeper understanding of microbiology, particularly in the area of bacterial
cell wall synthesis and recycling. In spite of this knowledge, which has enabled design of new
even more effective therapeutics to combat bacterial infection and has provided new research
tools, antibiotic resistance remains a worldwide health care problem.
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INTRODUCTION
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The concept of using of chemicals to alleviate diseases, particularly infectious diseases,
dates back to the Ancient Egypt, Babylon, the Far East and the Incas (1). These early
examples of remedies include applying molds to opened cuts and wounds, and eating
radishes, leeks, garlic and onions that are now known to be anti-bacterial.
The possibility of one organism interfering with the growth of another has been the subject
of intense investigation since the early days of microbiology, In 1871, Sir John BurdonSanderson observed that media exposed to air rapidly became turbid with bacteria, but if a
Penicillium mold happened to grow on the surface of the broth, less turbidity ensued (2).
Others, including William Roberts, John Tyndall and Joseph Lister reported similar
observations with Penicillium (3–5). Although perhaps only Roberts and Lister realized that
their findings could be due to the action of an antibacterial compound, these observations are
noteworthy nonetheless (6). One of the earliest references to the therapeutic potential of the
inhibition of bacterial growth by other microorganisms was in Pasteur and Joubert’s
descripton of the inhibition of anthrax by air-borne organisms (7). Further evidence that
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Lister understood the clinical relevance of the antagonism is his reported treatment of
infected wounds with Penicillium in 1884 (6).
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PRE-PENICILLIN ERA
Although many observed microbial antagonism, the concept that the phenomenon was
caused by the production of a compound by one microorganism that could kill another was
not immediately apparent. For example, in a later work, Tyndall surmised that the bacterial
growth inhibition observed in the presence of Penicillium was due to limiting oxygen
conditions (8). Initial work by Corneil and Babes and substantiated by experiments by
Garre, firmly established that microbial antagonism was caused by the action of a diffusible
substance produced by one organism on another (9,10). By the end of the 19th century, not
only was this phenomenon well accepted, but it was also given a name – antibiosis (11).
A few researches showing the contradictory effects between Penicillium and bacteria
predate the now famous studies of Alexander Fleming and received little attention until after
the clinical importance of penicillin was established. While completing his doctoral degree
in 1897, Ernest Duschesne found antagonism between Penicilium and Escherichia coli in
vitro. He then found that co-injection of a normally lethal dose of Salmonella typhi, the
causative agent of typhoid fever, with Penicillium glaucum prevented the animals from
contracting typhoid (12).
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Another notable pioneer was Gratia, a Belgian scientist who did ground-breaking research
on the phenomenon of bacteriolysis and its application to the defeat of bacteria pathogens
(13). In classic experiments performed in 1925–1926, Gratia and his assistants exposed a 2
% water agar plate containing dead Staphylococcus to the laboratory air. A culture of white
actinomycete grew on the plate surrounded by a clear zone of dissolved bacteria. This
airborne contaminant was next demonstrated to attack killed cultures of Pseudomonas
aeruginosa, Mycobacterium tuberculosis and Escherichia coli. Gratia called the lytic agent
“mycolysate”. The mycolysate was non-toxic when introduced into guinea pigs and rabbits.
In addition, he used the mycolysate on human subjects in 1930 and obtained considerable
success (13).
From these accounts, Fleming was therefore not the first to observe antibiosis between the
fungal and bacteria in a vessel, but without controversy, he was the first to study the
substance he termed “penicillin”.

BETA-LACTAM DISCOVERY AND DEVELOPMENT FOR CLINICAL USE
NIH-PA Author Manuscript

Discovery of penicillin
The story began in 1921. Alexander Fleming (Fig. 1), a Scottish bacteriologist, suffering
from a common cold, inoculated agar plates with his own nasal secretion to determine the
change of his nasal bacterial flora (14). No colonies appeared for several days. This
suggested the presence of a diffusible substance in the nasal secretion that affected the
ability of bacteria to grow at all. The substance, a protein Fleming named lysozyme, was
found to be a potent enzyme capable of dissolving the cell wall and causing lysis in many
Gram-positive bacteria. The discovery of lysozyme paved the path for the later serendipitous
discovery of penicillin.
In the summer and early fall of 1928, Fleming was studying the relationship between colony
morphology of Staphylococcus and their virulence (14). Before leaving for vacation, he
inoculated culture plates with Staphylococcus colonies and stacked the plates on the corner
of his laboratory bench. When he returned, he found several cultures contaminated with
molds. He discarded the contaminated plates into a Lysol basin. He worked with many
APMIS. Author manuscript; available in PMC 2011 January 1.
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cultures that day, and a few culture plates rested above the level of the liquid antiseptic,
escaping the disinfectant. The next day, in the process of describing his experiments to a
colleague, Fleming dug up some previously discarded culture plates (14). Upon reexamination, one of the plates contained a contaminating mold whose presence seemed to be
influencing the morphology of the surrounding Staphylococcus colonies: colonies in
proximity to the mold were transparent and seemed to be undergoing lysis. This observation
was reminiscent of what Fleming had previously seen with lysozyme, led him to realize that
the mold contained a microbial antagonistic property.
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Fleming carefully sub-cultured and preserved the Penicillium notatum, which he originally
described as Penicillium rubrum. He described the growth property of the mold, elaborated
an extraction procedure and designed a rapid antimicrobial assay (15). Fleming, together
with his assistants Dr. Stuart Craddock and Mr. Frederick Ridley, set out to purify the the
lytic agent, which he dubbed “penicillin”, released into the broth by the mold (16).
According to Craddock’s notebook, Craddock and Ridley found that activity could be
recovered from broth and concentrated by evaporation as long as the pH was kept at 6.9 or
below and that the activity could be extracted with ether, acetone, or alcohol (16). Serial
dilutions of these extracts inhibited growth of Staphylococci, Streptococcus pyrogenes and
Pneumococcus cultures. However, the active ingredient did not harm Escherichia coli,
Haemophilus influenzae, Salmonella typhi, Pseudomonas aeruginosa, Bacillus proteus or
Vibrio chloerae and thus was found to be useful in culturing these organisms. The extract
was also applied directly to animal tissues, specifically wounds and human eyes, and found
to be neither toxic nor irritating (15). These legendary experiments formed the foundation
for the subsequent purification of penicillin and an easy antimicrobial testing technique
which is being widely used today. However, Fleming did not extend his work to clinical
study because he was not able to purify enough penicillin for the experiments. So, while the
discovery was made in 1928, the use of penicillin as a therapeutic agent to treat infections
did not happen until the 1940s.
Bringing penicillin to bedside
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In 1939, 12 years after the Fleming’s ground-breaking discovery, Howard Walter Florey
(Fig. 1), Head of the Sir William Dunn School of Pathology, Oxford University, England,
obtained a $25,000 research grant for a period of five years from the Rockefeller Foundation
to investigate the chemical and biologic properties of antibacterial substances produced by
molds and other bacteria (17). He recruited Ernst Chain to develop the biochemical
methodologies (Fig. 1). Among the molds, they selected Fleming’s strain of Penicillium
notatum for further study because of its potent antimicrobial activity reported by Fleming
(16). Florey, Chain and eight coworkers, became legendary for the progress made on
Fleming’s penicillin in a surprisingly short period. In August 1940, they reported successful
use of penicillin to cure infections in mice, rats and cats (18). A year later, the first clinical
use of penicillin in 10 human subjects suffering from S. aureus infection was described
extensively (19).
With the initial success, the Oxford group was prepared to enter the next phase, a large-scale
clinical trial involving 100 patients. However, these experiments required an enormous
amount of penicillin, which was impossible to be manufactured in a small laboratory.
Hence, Florey and Heatley, another group member, crossed the Atlantic Ocean to the United
States of America in June 1941 to seek aid in mass producing penicillin (20). Through
several contacts, they were introduced into the new large scale fermentation laboratory, the
Northern Regional Research Laboratory of the Department of Agriculture at Peoria, Illinois.
(20). In Peoria, they were able to isolate a novel Penicillium strain, Penicillium
chrysogenum that produced substantially more penicillin than previously used strains. This
work began to stimulate the interest of several pharmaceutical firms, among others, Charles
APMIS. Author manuscript; available in PMC 2011 January 1.
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Pfizer & Co., E.R. Squibb & Sons, and Merck & Co. as well as the government (17,21). The
strong monetary investment from these firms enabled the mass production of penicillin. This
led to multiple large-scale clinical trials in England and in the United States in late 1942 that
continued into 1943 (22–27). By 1946, a year after the Nobel Prize for Medicine was
awarded to Fleming, Florey and Chain, penicillin was finally available in the open market.
Penicillin as β-lactam
The work at the Northern Regional Research Laboratory also revealed that different strains,
culture conditions, and media result in the production of different penicillin compounds.
Penicillin from the United States strain was successfully crystallized and analyzed at E.R.
Squibb & Sons (17) and Florey’s group subsequently crystallized the compound from the
English strain (28). Florey and colleagues demonstrated that their strain used for the English
clinical trials was primarily 2-pentenylpenicillin (Penicillin F or I) while the United States
penicillin (Penicillin G or Penicillin II) was mainly benzyl-penicillin (29). It was later shown
that both forms of penicillin contained β-lactam rings (Fig. 2).
β-lactam derivatives
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With the diverse chemical structure of β-lactam molecules and their respective antibacterial
potency, chemists were eager to look beyond what nature had supplied, and how science
could contribute and substitute. Early work using different fermentation conditions were not
very successful (30). The β-lactam nucleus, 6-aminopenicillanic acid (6-APA; Fig. 2)
proved to be the key in penicillin synthesis and modification. J.C. Sheehan produced
Penicillin V by acylation of chemically synthesized 6-APA (31). This important piece of
work opened up the floodgate where novel beta-lactam agents could be mass-produced by
adding unusual side chains to 6-APA. Thereafter, semi-synthetic β-lactam compounds have
been developed continuously and systematically. For example, methicillin, approved for
clinical use in the United States in 1960, was the first semi-synthetic penicillin introduced to
resist hydrolysis by penicillinase (32). More significantly, a semi-synthetic compound
effective against Pseudomonas aeruginosa, carbenicillin, a penicillin analogue with a
carboxyl group in place of amino group of ampicillin, was introduced in 1967 (33).
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Though the generation of semi-synthetic compounds presented a great opportunity, natural
sources continued to be explored. Abraham and Newton isolated cephalosporin C from a
strain of Cephalosporium acremonium (34). This compound generated an entirely new
family of β-lactam antibiotics because instead of 6-APA, it possesses a nucleus of 7aminocephalosporinic acid (7-ACA; Fig. 2). Using 7-ACA as the precursor, several
generations of cephalosporins with potent broad-spectrum activity have been synthesized.
Many related naturally occurring compounds with important antibiotic activity were isolated
from bacteria. These include carbapenem from Streptomyces spp.(35), and monobactam
from Pseudomonas acidophila (36), Chromobacterium violaceum (37) and Agrobacterium
radiobacter (38). Penem and monobactam contained different β-lactam nuclei from 6-APA
and 7-ACA. Derivatives of these compounds, either naturally-occurring or semi-synthetic,
further expanded the spectrum of β-lactam agents.

β-LACTAM MECHANISM OF ACTION
Interest quickly developed, after the introduction of penicillin, as to the mechanism of
penicillin action on bacteria. Investigations of the mode of action of β-lactam antibiotics had
progressed through several seemingly independent routes. These routes included (1)
physiological analysis of the β-lactam effects on growth, viability, shape division and
integrity of bacterial cells; (2) biochemical analysis of the cell wall structure and the
enzymes involved in its biosynthesis; (3) biophysical analysis of the cellular components

APMIS. Author manuscript; available in PMC 2011 January 1.

Kong et al.

Page 5

NIH-PA Author Manuscript

that tightly bind penicillin and attempts at correlating this binding with its physiological
effects; and (4) genetic analysis of mutants with altered response to the β-lactam antibiotics.
These lines of research ultimately converged and became coherent. Readers are encouraged
to seek other recent reviews for more comprehensive overviews of specific topics of interest
(39–41).
Physiological analysis
Gardner observed that at low concentrations of penicillin, bacteria formed filaments (42).
This provided an early indication that penicillin interferes with the maintenance of cell
shape. In a subsequent study, using different concentration of penicillin, Duguid showed that
penicillin interfered with cell division and maintenance of the cell structures (43). These
morphological changes suggested penicillin inhibited the synthesis of an unknown outer
supporting cell wall structure (the nature of the supporting wall was not known at that time).
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Research on the bacterial cell wall, particularly the murein, was revived when the link
between β-lactam antibiotic and cell wall was established. The earliest documentation of the
presence of bacterial cell wall was traced as early as the age of Anthony van Leeuwonhoek.
Under his microscope, he observed that the bacteria were bonded by some sort of structure
and expressed his hope to resolve the question of what hold them together (44). This turned
out to be a nontrivial problem. Hans Christian Gram, a Danish bacteriologist, devised a
staining procedure that allowed him to observe colored bacteria under light microscope (45).
Since then, his technique has been widely adopted and used to classify bacteria into two
categories: the Gram-positive and the Gram-negative (45). Although a variety of
distinguishing features or chemical differences in eubacteria have been suggested as being
important for differentiating Gram-positive versus Gram-negative organisms (45), it is
apparent that the murein content of the cell wall is the primary differentiating architecture
(46). The breathtaking first thin-section images of Bacillus cereus vividly demonstrated the
bacterial surfaces and architecture of the cell wall making it apparent, for the first time, that
the cell wall of Gram-positive bacteria was predominately single-layered (47). On the other
hand, the cell wall of Gram-negative bacteria was controversial. It was not until Umeda’s
group in Japan used the freeze-substitution cryotechnique on Escherichia coli. The resulting
Gram-negative images were so remarkable that microbiologists consequently re-evaluated
their previous analysis (48). The periplasmic term was coined when Kellenberger’s group
from Switzerland produced tangible microscopic images of a rich, dense periplasmic space
of Escherichia coli’s cell envelope (49).
Biochemical analysis
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Bacterial cell wall biology was a relative newcomer to the scene of biochemical research in
the 1950s. The first biochemical clue to the site of penicillin action was provided by Park
and Johnson (50,51) who demonstrated that several novel uridine peptides accumulated in
the cytoplasm of penicillin-treated S. aurues. Park and Strominger subsequently observed
that the sugar and amino acid compositions of those uridine peptides were similar to those of
the bacterial cell wall, suggesting that they were cell wall precursors which accumulated as a
result of penicillin inhibition of cell wall biosynthesis (52). Originally, molecules comprised
of approximately equal proportions of protein and sugar components were called
peptidoglycans and the peptidoglycan making up the bacterial cell envelope were referred to
as murein. Over time, these terms became used interchangeably as they are in this review.
Murein sacculus refers exclusively to the rigid murein polymer that is present in the cell
envelope.
Ironically, prior to 1951, virtually nothing was known about the chemical composition of
bacterial envelopes beyond the fact that such well-known structural polysaccharides of plant
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cell walls as cellulose and chitin were absent. In 1951, Salton and Horne described a largescale method for cell wall isolation (53). This technique was based on the fact that cell walls
are physically quite resistant to mechanical stress. Electron microscopic illustrations
accompanying every step of purification, showed that there was no gross physical
contamination from other cellular compounds (53). Qualitative examinations of the purified
cell walls from a large number of Gram-positive eubacteria demonstrated the presence of Nacetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) in all these cellular
extracts (54,55). In addition, the amino acids glycine, D-glutamic acid, D- and L-alanine and
L-lysine were detected in each cell wall preparation (Table 1; (56)). Four amino acids were
present in the form of a tetrapepide whose sequence was determined to be L-alanyl-Dglutamyl-L-lysyl-D-alanine (Fig. 3). Glycine was present as an interpeptide cross-bridge.
These data correlated well with the first general hypothesis about the basal component of
cell wall structure, namely mucopeptides, consisting of a hexosamine which is either
GlcNAc and MurNAc and a peptide component made up of alanine, glutamic acid, glycine
and either diaminopimelic acid or lysine (Fig. 3; (55,57)). In fact, this compound was
exceedingly similar to the nucleotides Park obvserved accumulating in S. aureus as a result
of penicillin attack resulting in the convergence of these two lines of investigation (52).
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Though early investigation on Gram-positive organisms successfully elucidated the
chemical structure of bacterial cell wall, it became apparent that this was not the case in
Gram-negative bacteria when the purified Gram-negative cell wall was subjected to
chemical examination. Specifically, the Gram-negative cell wall preparation contained more
lipid and less amino sugar than the Gram-positive cell wall (58). The detection of a lipid
component in the Gram-negative’s cell wall was not surprising because the presence of
lipopolysaccharide was known from the 18th century as the substance that was associated
with fever and diseases (59). Furthermore, a full range of amino acids, presumably
corresponding to normal protein structures, were identified (58). However, the observations
that in Escherichia coli, lysis occurred by treatment with lysozyme, and that penicillin
produced osmotic fragility, suggested the presence of peptidoglycan (60).
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Although the basic biochemical compositions were known, the architecture of the Gramnegative bacterial cell wall remained elusive. Elegant work by Weidel and Primosigh
indicated that phenol could remove the lipopolysaccharide layer (80 % of the whole) from
Escherichia coli, leaving behind a layer, consisting of sugars, lipids and amino acids. This
layer retained the shape of the intact wall and was, therefore, assumed to be responsible for
its rigidity (61). Subsequently, modified purification procedures allowed them to show that
the ‘wall’ remaining after phenol treatment contained glucosamine, muramic acid, and a
preponderance of alanine, glutamic acid, and diaminopimelic acid (62). Quantitative
dissection revealed that various Escherichia coli strains gave essentially the same molar
proportions as S. aureus: 1.0 glutamic acid, 1.5 alanine, 0.2 lysine, 0.65 diaminopimelic
acid, 0.8 glucosamine and 0.5 muramic acid (63). Essentially, the same mucopeptide
composition is found in the cell walls of a wide range of Gram-negative species. The
absence of glycine in the Gram-negative cell wall strongly indicated the absence of
interpeptide cross-bridges (Fig. 3).
Murein biosynthesis
Murein is a macromolecule of enormous size. It completely envelopes and maintains the
structure of bacteria. The realization of the mode of β-lactam agents on the murein layer is
an essential prelude to the study of its biosynthesis. Ten years were devoted to elucidating
the enzymatic reactions involved in the biosynthesis of the complex murein molecules. Key
enzymes involved in the murein synthesis and cell wall recycling and the E. coli and P.
aeruginosa genes encoding them are listed in Table 2.
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Biosynthesis of the cell wall is comprised of three distinct stages occurring at three distinct
sites in bacterial cells (64). The first site is in the cytoplasm. This chain of reactions is
initiated with the committed step in which a three-carbon phosphoenolpyruvic acid (PEP) is
attached to UDP-N-acetylglucosamine (UDP-GlcNAc), leading to the formation of UDP-Nacetylmuramic acid (UDP-MurNAc; Fig. 4). This is followed by an enzymatic addition of
amino acids in a stepwise manner, and finally to the production of UDP-MurNAc
pentapeptide, the compound first isolated by Park and Johnson (Fig. 4; (50)). The second
stage of the bacterial murein synthesis occurs at the cytoplasmic membrane of the cell. At
this site, the intracellular precursors, UDP-GlcNAc and UDP-MurNAc pentapeptide, are
joined at the sugar ends to form a linear murein with protruding short peptide chains at every
N-acetylmuramic acid sugar (Fig. 4). In addition, depending on the organism, the murein
peptides are modified. For the genus Staphylococcus, the α-carboxyl group of D-glutamic
acid in the pentapeptide is amidated to yield D-isoglutamic acid (65).
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The final transpeptidation step does not require any input of energy. In vivo investigation of
crude protein preparations of Escherichia coli showed that there are in fact two concomitant
transpeptidation reactions (66,67). Cross-linking between two murein strands is introduced
by transpeptidase, followed by a second reaction catalyzed by a D-alanine carboxypeptidase
in which the terminal D-alanine residue of the pentapeptide in the other strand is removed
(68–70). Among the enzymatic reactions, only the transpeptidase and D-alanine
carboxypeptidease are sensitive to β-lactam antibiotics (66). However, the inhibition of the
D-alanine carboxypeptidase enzyme occurs at a much lower MIC than that for the organism
(66,67). Thus, it is proposed that the inhibition of this activity is not lethal. In sharp contrast,
the concentration required to inhibit growth was virtually similar to the concentration
required to halt the activity of transpeptidase, the enzyme carrying out the actual crosslinking reaction, suggesting that this is the crucial step inhibited by β-lactam antibiotics
(66,67,71).
Penicillin is a cyclic dipeptide of two amino acids, L-cysteine and D-valine. The
conformation of one edge of the penicillin molecule is nearly identical as the conformation
of the backbone of the D-alanyl-D-alanine (Fig. 2). A crucial feature in this case is the fact
that the highly reactive CO-N bond in the β-lactam ring of the penicillin molecule lies in
exactly the same position as the CO-N bond in D-alanyl-D-alanine which is the target of
transpeptidation (Fig. 2). Owing to the striking structural similarity, it was thus hypothesized
that penicillin acts as a substrate analog, binding to the substrate-anchoring site normally
occupied by D-alanyl-D-alanine (69).
Biophysical analysis
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Transpeptidases have been characterized as penicillin-sensitive proteins since their activity
is specifically prevented by the covalent binding of β-lactam antibiotics to their active site
(72). The inference that transpeptidase is a penicillin-binding protein (PBP) converges yet
another line of independent research to the overall understanding of the penicillin action.
As early as 1949, ingenious work had employed radioactive penicillin to locate the site of its
action on bacterial cells (73–76). These studies clearly indicated that penicillin bound a
definite trace target, termed penicillin-binding component (PBC (74)). It appeared that the
entire penicillin molecule reacted with PBC. Once bound, radioactive penicillin was unable
to be removed by neutral buffers, acids or detergent, but treatment with dilute alkali released
it as penicilloic acid (74,76,77). In addition, the PBC was destroyed at high temperature and
treatment with strong solvents indicative of protein components (78). Taken together, this
suggested penicillin is covalently bound to PBC. When the PBC-penicillin complex was
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the
PBC resolved into several proteins ranging in molecular weight from 40 to 90 kDa (79).
APMIS. Author manuscript; available in PMC 2011 January 1.
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These proteins were named penicillin-binding proteins (PBP) and numbered according to
their descending molecular weights. The number of PBPs, their molecular weight, their
concentration (molecule per cell) and their sensitivity to β-lactam antibiotics of these
proteins varied widely between bacterial species (e.g. Table 2; (80)). Some of the lowmolecular-weight PBPs, PBP5, PBP6 and PBP7, were found abundantly in bacilli but not in
cocci (80). Gram-positive cocci, for example the two cousins, Staphylococcus aureus and
Staphylococcus epididermis, express only four penicillin-binding enzymes, whereas Bacillus
subtilis and Bacillus cereus harbor seven to eight PBPs (80,81). In Escherichia coli, PBP1–6
were identified using radioactive benzyl-penicillin (79). Similar numbers of PBP were also
found in Pseudomonas aeruginosa, Entaerobacter cloacae, Salmonella enteric serovar
Typhimurium (S. Typhimurium) and Serratia marcescens (80).
Genetic analysis
Functional and morphological correlations of the PBPs strongly relied on their binding
specificity of β-lactam antibiotics and isolation of temperature-sensitive mutants. Since
PBPs were named based on their SDS-PAGE migration, PBP nomenclature is organism
dependent. For example, Escherichia coli PBP2 is most similar to Staphylococcus aureus
PBP3. The numbering system used below is based upon Escherichia coli PBPs. Much has
been elucidated about the structure and biochemical properties of PBPs. Readers are referred
to recent reviews focusing on PBPs (82–85).
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PBP1—Cephaloridine, a cephalosporin agent which blocks cell elongation at sub-inhibitory
concentration, has the highest affinity for Escherichia coli PBP1, suggesting that PBP1
might be involved in cell elongation (86). The high-molecular-weight PBP1 band on SDSPAGE was actually composed of two polypeptides (79). Spratt first observed the resolution
of these two closely related proteins into two fragments, but this was inconclusive as the
separation was inconsistent (79). Subsequent modification of the SDS-PAGE technique
allowed resolution of PBP1 into two distinct components, PBP1a and PBP1b (87).
The gene coding for PBP1a was mapped to ponA or mrcA using N-methyl-N-nitro-Nnitrosoguanidine chemical treatment (87,88). Strains containing mutations in ponA/mrcA
appeared to grow normally, suggesting that that PBP1a might have a subtle role in cell
growth and morphology (87,88). However, PBP1a mutants underwent a slow rate of βlactam induced lysis, suggesting involvement in murein metabolism (87). Subsequent
studies showed that PBP1a catalyzed the polymerization of the glycan subunit and
crosslinking of muropeptides (88).
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PBP1b could be further resolved into at least three bands (88); however, chemical
mutagenesis of a single gene, ponB or mrcB, resulted in the loss of all three fragments. The
three could be recovered simultaneously by P1 transduction of the wild-type gene located at
3.3 minute of the Escherichia coli chromosome, suggesting that PBP1b could exist in three
isoforms (88). By examining the in vitro incorporation of radioactive UDP-MurNAcpentapeptide into the murein, membrane fractions isolated from ponB/mrcB mutants had
significantly decreased murein biosynthetic activity, indicating that PBP1b catalyzed the
majority of this activity in vitro (88). Subsequently, PBP1b was functionally indicated to be
responsible for transglycosylase and DD-transpeptidase enzymatic reactions (89–91).
PBP1a and PBP1b differ markedly in their affinities for several β-lactams. For example,
cephalothin and cephaloridine both bind PBP1a strongly, while PBP1b has high affinity only
for cephaloridine (87). In agreement with this, Escherichia coli cells lacking PBP1b are
hypersensitive to cephalothin, owing to the binding of this β-lactam antibiotic to the PBP1a
(88). Although individual loss of PBP1a or PBP1b did not confer thermosensitive growth,
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the loss of both proteins was lethal, indicative of redundancy in the system (90). Inhibition
of both PBPs was necessary to prevent cell elongation and thereby induce lysis (90).

NIH-PA Author Manuscript

PBP1c, a third penicillin-binding protein related to PBP1a and PBP1b, has also been
identified in Escherichia coli (92). Unlike PBP1a and PBP1b which function as both
transglycosidases and transpeptidases, PBP1c appears to only function as a transglycosylase.
Overexpression of PBP1c, which is encoded by pbp1c located at 56.9 min on the
Escherichia coli chromosome, cannot suppress the effect of mutating both PBP1a and
PBP1b. Mutation in PBP1c does affect cell murein synthesis (92).
PBP2—PBP2 was the first penicillin-binding protein to be dissected functionally due to the
ability of this enzyme to specifically bind to mecillinam (79). Covalent binding of
mecillinam to PBP2 caused alteration in Escherichia coli shape from rod into ovoid (93).
This morphologic alteration allowed the isolation of mutants lacking PBP2 after an intensive
chemical mutagenesis (94). These thermolabile mutants grew slowly as rod-shaped cells at
30°C and became round cells upon temperature shift to 42°C (94). Hence, PBP2 was
thought to be the major protein involved in maintenance of cell shape. Absence of PBP2
also caused inhibition of cell division and delayed muropeptide synthesis (94,95).
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The actual functions of PBP2 attracted a lot of attention. In vitro, upon the presence of
mecillinam, the carboxypeptidase, transpeptidase and endopeptidase activities were
unaffected, suggesting that PBP2 might catalyze a novel reaction (93,96). However, it was
also postulated that PBP2 mediated a topologically restricted transpeptidase reaction,
perhaps during a specific phase of the cell cycle. Several lines of evidence agreed with this
postulation:
•

Inactivation of PBP2 resulted in a doubling of the Escherichia coli cell wall
anhydromuramic acid content, thus implicating PBP in cell-wall glycan chainlength regulation (97).

•

In the presence of cefsulodin and cefmetazole, cephalosporins that bind to all PBPs
but PBP2, the murein synthesized acquired a degree of cross-linkage even higher
than the control cells, demonstrating that PBP2, or other proteins, might have a
transpeptidase activity in vivo able to produce a highly cross-linked peptidoglycan
(95).

•

A mutation in ponB or mrcB, encoding PBP1b, resulted in the over-production of
PBP1a and PBP2. This was consistent with the suggestion that PBP2 might act to
ensure that new initiation sites for elongation were introduced with the correct rod
orientation (86).
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These data argued that in the absence of active PBP2, novel glycan chains might be utilized
preferentially by the septum-forming enzyme system resulting in growth as round cells.
(98).
Because the strains lacking PBP2 were isolated upon intensive chemical treatments,
mapping the gene encoding PBP2 was non-trivial. Several genes were found to be involved
in round-shaped morphology and mecillinam resistance. In fact, the earliest report that
associated the appearance spherical Escherichia coli with antibiotic resistance, interestingly,
pre-dated the discovery of PBPs (99). Normark, investigating the effect of ultraviolet light
tolerance, observed round-shaped Escherichia coli under the electron microscope when the
strains harbored a mutation in envB (99). This envB gene was subsequently mapped to the
64 minute of the chromosome (99). Half a decade later, a second gene, rodA, responsible for
coccal-shaped cells, was mapped to 15 min between the purE and pyrC loci (100).
Escherichia coli strains with mutation in rodA were also found to be tolerant to ultraviolet
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irradiation (100). Moreover, intensive chemical mutagenesis analysis mapped two other
genes at minute 14 (rodX) and 70 (rodY) that were involved in the maintenance of the rodshape (101). However, since the round-shaped morphology could be due to the mutation of
any of these genes, these reports did not correlate the morphological change to the loss of
PBP2 protein. Eventually, the gene encoding PBP2, with the concomitant loss of PBP2
protein, was mapped to a region at 14.4 minute (88,102). Using a series of defective lambda
transducing phage, the region was mapped to a 12-kb DNA containing the lip-dacA-rodApbpA-leuS region (103). This cluster of genes was involved in cell shape determination and
murein synthesis (103). Analysis of the proteins produced from lambda transducing phage
carrying a well-defined DNA fragment showed that pbpA encoded PBP2, whereas dacA
coded for PBP5 (103). Although mutation in the rodA gene resulted in spherical cells, loss
of RodA did not affect the PBP2 activity (103). RodA was later found to act synergistically
with PbpA as transglycosylase and transpeptidase (104). Elegant genetic analysis of pbpA
demonstrated that pbpA spherical mutants could be isolated that retained penicillin binding
activity (98). Further analysis showed that deletion of pbpA is lethal, but may be suppressed
by overexpression of ftsZ, either directly or by increasing the intracellular ppGpp pool
(105,106). Together, this suggests that PBP2 plays an essential role in cell division.
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PBP3—Escherichia coli strains expressing temperature-sensitive PBP3 mutated proteins
were isolated from nitrosoguanine mutagenesis (79). At the permissive temperature of 30
°C, these mutants appeared slightly longer than the parental strain (102). On shifting to the
restrictive temperature of 42 °C, cell division ceased. But, the continuous increase in cell
density and the incorporation of 3H-thymine suggested that cell growth and DNA replication
were not affected in the absence of PBP3 at restrictive temperature. As a result of
continuous replication without division, long filamentous polynucleated Escherichia coli
was observed (102). This observation strongly argued that PBP3 was an essential celldivision protein. Supporting evidence for its role in cell division came from the use of
PBP3-specific β-lactam antibiotics, furazlocillin and piperacillin (107). PBP3 is recruited to
the septal ring where it functions as a transpeptidase to crosslink the peptidoglycan at the
division septum (108,109). Due to its function in cell division, PBP3 is also known as FtsI.
Biochemically, at the permissive temperature, both [14C]-diaminopimelic acid incorporation
into murein of intact cells and [14C] N-acetylglucosamine incorporation into murein were
reduced in septating PBP3 mutants, as compared to the wild-type while no inhibition was
detected in filaments growing at the nonpermissive temperature (108). The authors
suggested that PBP3 is involved in transpeptidation of muropeptides exclusively for septal
murein synthesis but not for the elongating murein production (107,108).
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Low molecular weight PBPs—The lower molecular weight PBPs 4, 5 and 6 were
shown as the major DD-carboxypeptidases (67). These enzymes displace the terminal Dalanine residue from one of the two peptide chains to form crosslinked murein (67). It was
argued that DD-carboxypeptidase regulated the extent of cross-linking in murein by
removing the terminal D-alanine from a proportion of the pentapeptide side chains of
nascent peptidoglycan, thus preventing their involvement in cross-links (67). This DDcarboxypeptidase activity was divided into two enzymatic reactions, namely IA and IB, each
catalyzed by different PBPs (67,110).
•

Enzyme IA was shown to catalyze DD-carboxypeptidase and transpeptidase
reactions, bind to [14C]-penicillin G, confer a weak penicillinase activity, but was
devoid of endopeptidase activity (110).

•

Enzyme IB was demonstrated to catalyze DD-carboxypeptidase and endopeptidase
activities, confer weak penicillinase activity, but not bind [14C]-penicillin G and
had poor transpeptidase activity (110).
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PBP4—Escherichia coli strains lacking the highly penicillin-sensitive activities of DDcarboxypeptidase IB and DD-endopeptidase showed a concomitant loss of PBP4 (111,112).
This mutation was mapped to the dacB gene located at 68 minute on the Escherichia coli
map (112). These mutants grew normally under a wide range of growth conditions,
suggesting that PBP4 was not essential for the growth of Escherichia coli under laboratory
conditions (88,111). However, overexpression of PBP4 showed an increase of DDcarboxypeptidase and DD-endopeptidase, which did not alter the transpeptidation reaction
(113). PBP4 was demonstrated as the only PBP of Escherichia coli that possessed DDendopeptidase activity. This enzyme was able to cleave the D-alanyl-γ-meso-2,6diaminopimelyl peptide bond in the crosslinks of murein (114).
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PBP5—Purified DD-alanine carboxypeptidase IA activity in Escherichia coli was
attributed to two polypeptides (115). Both proteins bound strongly to benyzlpenicillin and
were identified as PBP5 and PBP6 (79). These membrane-bound proteins were shown to
catalyze a transpeptidase reaction and had a weak penicillinase activity (110). Loss of PBP5
proteins could be complemented with P1 phage that carried the 14 minute region of the
chromosome, indicating that PBP5 gene was located within the lip-leuS region (116). Using
lambda transducing phage carrying well-defined DNA fragments, the gene encoding PBP5
was mapped to dacA (103). Mutation in dacA abolished the DD-alanine carboxypeptidase
IA activity, rendered the cells sensitive to penicillin, though they exhibited normal
morphology (117). A dacA dacB double mutant demonstrated a negligible carboxypeptidase
activity, suggesting that PBP4 and PBP5 contributed at least 90 % of the DDcarboxypeptidase activity (117).
PBP6—The dacC-encoded PBP6 protein shares 62 % sequence identity with PBP5 (118).
Both purified PBP5 and PBP6 were able to catalyze identical reactions but PBP5 had a
three- to fourfold higher specific activity towards uncross-linked peptidoglycan than PBP6
(119). Deletion of dacC had no effect on cell morphology and growth rate (120). However,
strains lacking PBP6 showed a very slight increase in antibiotic sensitivity (120). However,
comparison of the expression of PBP5 and PBP6 at different phases of growth exposed the
temporally differential functions of PBP5 and PBP6. The concentration of PBP5 remained
fairly constant throughout all phases, whereas the amount of PBP6 increased two- to tenfold in stationary phase as compared to exponential phases (121). This growth-phase
dependent expression of PBP6 strongly suggested that it might be involved in stabilizing the
murein at stationary phase.
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Another low molecular weight PBP that is similar to PBP5 and PBP6 was identified in
Escherichia coli, PBP6b (122). PBP6b has DD-carboxypeptidase activity and binds [3H]
benzylpenicillin. The gene encoding PBP6b, dacD, is located at minute 44 on the
Escherichia coli chromosome and was identified using the Kohara lambda phage library
(122). Like PBP5 and PBP6, PBP6b is non-essential for viability (122).
PBP7/8—PBP7 and PBP8 were characterized more recently than most of the other PBPs in
part due to their irreproducible presence in bacterial preparations. PBP8 is an OmpT
proteolytic product of PBP7 (123). PBP8 has been shown to be a D-alanyl-DAPendopeptidase (124) and increased expression is related to increased cephaloridine and
ceftazidime resistance (125). Both are soluble perplasmic proteins that are peripherally
associated with the membrane. Use of the Kohara lambda phage miniset library narrowed
the genomic location of the PBP7-encoding gene to 47.8 and 48 min on the Escherichia coli
chromosome (126). Subsequent subcloning of one open reading frame, yohB now renamed
pbpG, and insertional mutagenesis confirmed that pbpG encoded PBP7.
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The introduction of penicillin from laboratory to bedside heralded a new era in the clinical
settings. Physicians had a landslide victory in treating many dominating lethal infectious
diseases such as meningitis, tuberculosis, pneumonia and so forth. The development of other
classes of antibiotics, such as erythromycin, tetracyclines, and chloramphenicol, fully
strengthened the foundation of infection chemotherapy. Antimicrobial therapy provided
physicians with the ability to prevent some infections, to cure others and to curtail the
transmission of certain diseases. At the beginning of the twentieth century, infectious
diseases were the leading cause of death worldwide. The success of vaccination and the
discovery of antibiotics changed this trend. Between 1900 and 1980, in U.S., mortality from
infectious diseases fell from 797 to 36 per 100,000 individuals (127). In 1969, amid with the
success of vaccination and the development of antibiotics, the Surgeon General told the
United States Congress that it was time to ‘close the book on infectious diseases’ (128). The
availability and success of antibiotics resulted in a confidence that technology and modern
medicine would be victorious against infectious diseases. The emergence of outbreaks and
epidemics of antimicrobial resistant infections resulted in a re-evaluation of this optimism.

NIH-PA Author Manuscript

At the very beginning, resistance to antibacterial agents was recognized as a potential
problem. Resistance to penicillin was actually the focus of Alexander Fleming’s 1929
ground-breaking masterpiece where he exploited the advantage of the substance to eliminate
Staphylococcus and Streptococcus contamination and thus, isolated pure cultures of
Escherichia coli, Salmonella enterica serovar Typhi and Haemophilus influenzae (15). Yet,
the potential of penicillin as therapeutic agent overshadowed the resistance issue.
All was not lost as this report intrigued some scientists, particularly Edward Abraham and
Ernst Chain. They setup to answer the question of why some bacteria are more resistant than
others. In 1940, they found penicillinase enzyme in the culture fluid of a penicillin-resistant
Gram-negative rod that had contaminated Penicillium cultures and in an extract of
Escherichia coli, but detected no such activity in a penicillin-sensitive strain of
Staphylococcus aureus (18). The purified enzyme from Staphylococcus was able to
inactivate penicillin effectively (129). Thus, it was known from the beginning of the humanpathogen battle that bacteria have the ability to counteract the antibiotics. Furthermore,
Edward Abraham and his colleagues also demonstrated that cultures of staphylococci could
be made resistant by continuous subculture in the presence of the antibiotic in vitro (19).
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Within a year of introduction, four penicillin-resistant staphylococci strains were isolated
from patients during the course of treatment of localized infections (130). This was followed
by a number of reports showing the emergence of penicillin-resistant staphylococci (131–
133). This phenomenon did not raise an immediate alarm because the initial increase in
penicillin resistance could be compensated with an elevated dosage of the drug, as the
antibiotic was relatively safe and became more widely available and inexpensive (134). By
1947, just five years after its introduction, the majority of hospital isolates of Staphylococcus
aureus were resistant to penicillin G and six other common antibacterial agents, including
streptomycin, tetracycline and erythromycin (135). This prevalent inter-hospital spreading
Staphylococcus aureus strain 80/81 complex was the first encounter of multiple-resistant
pathogens (135). Barber in England was the first to call attention to the problem of the
increasing occurrence of penicillin-resistant staphylococci in hospitals (136–139).
Worldwide alarm of Staphylococcus aureus resistance quickly followed as reports emerged
from many hospitals and laboratories in the United States (135), Canada, Australia, Norway,
Sweden, Denmark, France, India and Chile (134).
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In the 1960s, analysis of the organisms associated with nosocomial infections shifted away
from Gram-positive species to Gram-negative species such as Escherichia coli, K.
pneumonia and Proteus mirabilis, a group of bacteria which scientists and bedside
physicians had little understanding (140). According to Finland’s longitudinal survey of the
panorama of infections, the introduction of antimicrobial agents was accompanied with
negative rather than positive overall impact to the patients (140). In fact, the potential
therapeutic effect was nullified by a shift towards more drug-resistant organism and seriousinfections by more virulent organisms. In addition, organisms challenged with antibiotics
increased their number, and enhanced their pathogenicity and invasiveness (141).
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On the other hand, the medicine renaissance increased the life expectancy, but not the life
quality, of the human race with sophisticated treatments, including intensive care for
terminal patients, artificial instrument insertions and chemotherapy of cancer patients. As a
result, there was a sudden surge of patients who were immuno-compromised or required
frequent medical attention. These events directly augmented the opportunity of the
infections of a group of pathogens such as Pseudomonas aeruginosa, Staphylococcus
epidermidis, Klebsiella pneumoniae and Serratia marcescens (140). Unlike Staphylococcus
aureus, Escherichia coli and Salmonella Typhi, this group of bacteria are successful
environmental organisms, evolutionarily equipped with an armory to counteract naturally
occurring growth inhibitors including naturally occurring antibiotics, antiseptics and heavy
metals (140).
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The failure of penicillin to be the magic bullet and the shift in infection pattern pushed
investigators to seek alternative routes. The age of ‘drug rejuvenation’ began with the
artificial synthesis of 6-Aminopenicillanic acid (31). This discovery allowed the rapid
introduction of β-lactam antibiotics by changing the chemical structures in vitro. For a short
period of time, drug company chemists managed to keep ahead in the race against antibiotic
resistance by making slight changes in the structures of their antibiotics. The synthesis of
semi-synthetic methicillin, which was β-lactamase stable, temporarily rescued the failure of
the penicillin (142). Meanwhile, the production of ampicillin, another semi-synthetic βlactam antibiotic, inhibited a wide range of Gram-negative organisms, including Escherichia
coli, Haemophilus influenzae, Salmonella Typhi and Shigella. As a result of the explosive
antibiotic development, the market was crowded with more than one hundred antibacterial
agents (143). Thinking that they had won a total victory, many pharmaceutical firms started
to withdraw the efforts to develop new antibiotics in the 1980s, instead focusing on drugs
for chronic illnesses such as heart disease, cancer and diabetes, the leading causes of
mortality and morbidity in developed countries (128). Thus far, antibiotics have been used
with unrestrained passion far surpassing the needs of management and infection control.
This is owing to an unorthodox belief that antibiotics play a life-saving role in all
debilitating diseases (144). Over the years, antibiotic resistance issues frequently come
under the spotlight in the media.
As the gruesome antibiotic resistance alarm became inescapable, international conferences,
workshops and other actions were organized to persuade funding agencies to take notice and
bring the issue to the forefront (145). In 1990, Gail Cassell, President of the American
Society of Microbiology (ASM) and a member of the advisory council of the National
Institutes of Allergy and Infectious Diseases (NIAID) warned, ‘we are at a very critical
crossroads in terms of readiness to deal with infectious diseases and antibiotic resistance
from a funding standpoint’ (145). Even though better monitoring or a surveillance program
could help prevent and manage outbreaks of antibiotic resistant disease, most scientists
argued that basic research on how bacteria defy antibiotics was equally pressing and
seriously lacking.
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β-lactam was the first antibiotic to be described (28). Consequently, resistance to β-lactam
antibiotics is the first to be understood. The most effective way for bacteria to counteract
these chemicals has been by producing β-lactamases, enzymes that inactivate the drugs by
hydrolyzing the β-lactam ring (18). Based on the sequence analysis, β-lactamases and the
PBPs are believed to diverge from a common ancestor. All PBPs possess β-lactam
catalyzing capability to a smaller extent. For instance, PBP5 was demonstrated to have the
highest β-lactamase activity. At pH 7.0 and 30°C, the half-life of penicilloyl-PBP5 was
averaged at 10 min (119). In addition, the monofunctional penicillin-binding DD-peptidases
and penicillin-hydrolyzing serine beta-lactamases retain the same tertiary folding, threemotif amino acid (Lys-Thr-Gly) sequence signature, serine-assisted catalytic mechanism and
active-site topology (Fig. 5 (72)).
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Thus far, more than 300 enzymes have been documented (146). Because of the diversity of
enzymatic characteristics of the many β-lactamases discovered, multiple attempts have been
made to categorize them since the late 1960s (147–150). Theseclassifications involve two
major approaches: the first and older one is based on the biochemical and functional
characteristics of the enzyme, whereas the second approach is based on the molecular
structure of the enzyme. In the former classification scheme, several criteria are used,
including the spectrum of antimicrobialsubstrate profile, enzyme inhibition profile,
hydrolysis rate (Vmax), binding affinity (Km), isoelectricfocusing (pI), protein molecular
weight, and amino acid composition (149,150). The molecular classification of β-lactamases
is based on the nucleotide and amino acid sequences in these enzymes. To date, four classes
are recognized (A-D), correlating with the functional classification. Classes A, C, and D act
by a serine based mechanism, whereas class B or metallo β-lactamasesneed zinc for their
action (147,148).
Ambler Class A
Ambler molecular class A was initially described in Gram-positive plasmids. However,
plasmid-, transposon- and chromosomally-mediated β-lactamases (VHS, PER, TEM and
SHV) in Gram-negative bacteria have also been reported (151). This class of enzymes,
dubbed penicillinases, exhibits the highest degree of sequence variability and kinetic
properties (152). Plasmid-encoded Ambler class A β-lactamases identified in Pseudomonas
aeruginosa are active against carbenicillin hence referred to as CARB or Pseudomonasspecific β-lactamases (PSE) (153,154). In addition, VHS-, PER- and TEM-derived βlactamases have also been reported in Pseudomonas aeruginosa (155).
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Ambler Class B
The Class B enzymes contain a small number of Zn2+ metallo-β-lactamases, whereby their
activities could be inhibited by EDTA (156). IMP-1 is the first metallo-β-lactamase
described in Pseudomonas aeruginosa (157). Its gene, blaIMP, appears to be dispersed
among Pseudomonas aeruginosa and other Gram-negative rods in Japan (158). An integronborne metallo-β-lactamase gene, blaVIM, which was originally described in Pseudomonas
aeruginosa isolated in Italy and is prevalently found in Greece, gives rise to the resistance of
meropenem and imipenem (159,160).
Ambler Class C
The Ambler Class C enzymes are active against cephalosporins, hence dubbed
cephalosporinases (161). They are chromosome-encoded and synthesized by most Gramnegative bacteria. The known sequences of these enzymes are highly conserved (162). The

APMIS. Author manuscript; available in PMC 2011 January 1.

Kong et al.

Page 15

Pseudomonas aeruginosa Class C cephalosporin-hydrolyzing chromosomal β-lactamase,
encoded by ampC (PA4110), has been cloned and sequenced (163).
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Ambler Class D
The enzymes belonging to the Class D group of β-lactamases are called oxacillinases as they
are able to degrade isoxazolyl β-lactams such as oxacillin and methicillin (164), while
clavulanic acid serves as a good inhibitor for these enzymes (165). Due to the structural
similarity between Class A and Class D enzymes, Couture et al suggested the use of the 26
conserved amino acid residues as the class D standard numbering scheme (DBL numeration)
(151). Plasmid- and transposon-mediated oxacillin-hydrolyzing β-lactamases in
Pseudomonas aeruginosa are common and complex. The characterization of a Pseudomonas
aeruginosa ampC mutant led to the discovery of a novel chromosomally-encoded Class D βlactamase, encoded by poxB [PA4511; (166)]. This Class D β-lactamase was independently
reported by Girlich et al., and the enzyme was named OXA-50 (167). However, sequence
analysis argues that PoxB is distinct from OXA enzymes (166). Nosocomial outbreak with
Pseudomonas aeruginosa extended-spectrum of Class D β-lactamases (ESBLs) was reported
(168) and more episodes are expected to arise in the near future.

THE CHROMOSOMAL β-LACTAMASE INDUCTION MECHANISM
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There are two kinds of chromosomal-encoded β-lactamases: constitutive and inducible. The
former is present at a predictable level under all circumstances, whereas the latter is
repressed in the absence of antibiotics and induced in the presence of β-lactam agents (169).
The analysis of chromosomal mediated β-lactamases revealed that in bacteria species that
possess a specific transcriptional regulatory system, synthesis of β-lactamase is inducible,
whereas in strains without this system, synthesis is usually constitutive (170,171).
The Gram-negative organisms possess chromosomally determined β-lactamases and the
types of β-lactamase produced are often species-specific (171). The inducible expression of
β-lactamases of Gram-negative bacteria suggests that this mode of bacterial resistance does
not involve a single-protein one-step mechanism. Indeed, genetic studies performed on
Enterobacter cloacae, Citrobacter freundii and Escherichia coli revealed at least five genes
found in three loci directly participate in β-lactam resistance. They are ampC, ampR, ampD,
ampE and ampG. Many human pathogens harbor AmpR and AmpC homologs, namely,
Burkholderia cepacia (172), Yersinia enterocolitica (173), Citrobacter freundii (174),
Enterobacter cloacae (175), Morganella morganii (176), Serratia marcescens (177),
Laribacter hongkongensis (178) and Ochrobactrum anthropi (179).
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ampC
The chromosomally encoded β-lactamases have been a subject of intense study since the
1980s (161). Most of these enzymes are cephalosporinases that are capable of hydrolyzing
third generation cephalosporins with low Vmax value and high Km values (161). They are
classified as the type I β-lactamases in the Richmond and Sykes scheme, and Class C
enzymes in Ambler’s classification (147,150). These are relatively large enzymes (30–42
kDa), usually with alkaline isoelectric points (150).
The chromosomal β-lactam hydrolyzing gene, ampC, of Escherichia coli K-12 was first to
be cloned and sequenced (180). This 1536-bp gene encodes a protein of 377 amino acids.
The first 19 amino acids form a signal peptide, suggesting that this protein is translated as a
precursor and transported into the periplasm as a mature 39.6 kDa enzyme (180). The AmpC
β-lactamase with substrate specificity for cephalosporins showed no significant sequence
homologies with β-lactamases of the Ambler’s Class A penicillinase or with the D-alanine
carboxypeptidases (161).
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The expression of AmpC in Escherichia coli K-12 was constitutively low in the absence of
β-lactam antibiotics (181). However, the amount of AmpC protein increased proportionately
with the growth rate and the nutrient availability (181). The checkpoint for the limited
expression of this enzyme was due to the presence of an attenuator located between the
promoter and the structural gene (182). This attenuator formed a stem-loop structure
followed by a string of U’s similar to a ρ-independent transcriptional terminator. Using an in
vitro transcription system, Jaurin et al. determined that less than one fourth of the transcripts
initiated at the promoter escape attenuation (182). This mechanism suggested the low
expression level of Escherichia coli β-lactamase.
Unlike the ampC of Escherichia coli K-12, the expression of Enterobacter cloacae ampC
was repressed in the absence of β-lactam antibiotics, and induced in the presence of β-lactam
agents (183,184). Intriguingly, the Enterobacter cloacae AmpC did not hydrolyze the third
generation cephalosporins (185). However, the authors concluded that β-lactamase
expression was solely responsible for resistance towards cefoperazone, cefotaxime,
ceftriaxone, ceftizoxime, ceftazidime and moxalactam because the cloning of the ampC gene
into Escherichia coli conferred an identical resistant pattern as Enterobacter cloacae (185).
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The β-lactamase gene of Citrobacter freundii was first cloned and transferred to Escherichia
coli as a 1.5-kb DNA fragment (186). The presence of this fragment in Escherichia coli
conferred a similar resistance profile to third generation of cephalosporins as the Citrobacter
freundii AmpC. Subsequently, the ampC of Citrobacter freundii strain OS60 was sequenced
and demonstrated to encode a 380 amino acid polypeptide with a 19 residual signal peptide
(187). The mature protein had a molecular weight of 39.8 kDa. It shared 77 % amino acid
identity with Escherichia coli K-12 AmpC (187).
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The ampC of Pseudomonas aeruginosa PAO1 was cloned and sequenced in the 1990’s
(163). Sequence analysis of the cloned 1.3 kb Pseudomonas aeruginosa chromosomal DNA
showed the presence of an ampC gene with a good homology to Enterobacter cloacae and
Citrobacter freundii AmpC proteins (163). When the putative ampC gene was transformed
into a non-β-lactamase-producing Pseudomonas aeruginosa strain, there was detectable
chromogenic activity (163). Western blotting using anti-Pseudomonas aeruginosa AmpC
antibody indicated that Pseudomonas aeruginosa AmpC had an approximate molecular
weight of 35.5 kDa (188). However, using crude protein extracts, the isoelectric point (pI) of
Pseudomonas aeruginosa β-lactamases was shown to be heterogenous (189). Multi-step
purification of the β-lactamase enzymes followed by protein sequencing suggests that the Cterminal truncations of AmpC might cause the variations in isoelectric point (190).
However, Gates et al. proposed that multiple β-lactamase genes might be present in
Pseudomonas aeruginosa (191).
Similar to Citrobacter freundii and Enterobacter cloacae, the expression of Pseudomonas
aeruginosa chromosomal β-lactamases could be induced in the presence of β-lactam
antibiotics (191). Examination of a large number of Pseudomonas aeruginosa clinical
strains revealed four patterns of β-lactamase expression: low-basal, inducible; moderatebasal, inducible; moderate-basal, constitutive; and high-basal, constitutive (189). Since the
existence of PoxB was not known, and the biochemical assays used were not sensitive
enough to distinguish these two β-lactamases, it was presumed that AmpC was
overexpressed in the hyperproducering clinical isolates (189). A high constitutive expression
of β-lactamase seen in Pseudomonas aeruginosa strains with ampR mutation suggests that
the clinical Pseudomonas aeruginosa isolates that are hyperproducing β-lactamase may
harbor poxB and a mutation in ampR (166). A Southern blot analysis of a few of these
clinical Pseudomonas aeruginosa isolates with ampR-and ampC-specific probes showed no
gross changes in the ampR-ampC intergenic DNA (192). This led the authors to rule out any
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changes in ampR and ampC genes, although this technique is not sensitive enough to detect
minor deletions or point mutations (192). In fact, one of these Pseudomonas aeruginosa βlactamase hyperproducers was shown to have a point mutation in ampR (193). It is not clear
if this clinical isolate harbors the poxB gene, though it has been demonstrated that poxB is
fairly ubiquitous and is found in chromosomes of both clinical and environmental
Pseudomonas aeruginosa isolates (166).
ampR
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Unlike Escherichia coli, the AmpC β-lactamases of Citrobacter freundii, Enterobacter
cloacae and Pseudomonas aeruginosa show differential expression in the absence and
presence of β-lactam antibiotics, suggesting that the regulatory systems governing ampC
gene expression are very different from that of Escherichia coli. Bergstrom et al. showed
that in Citrobacter freundii, the ampC gene was in close proximity to the fumarate reductase
operon (frd) as in Escherichia coli (194). However, whereas the frd operon and ampC
overlapped in Escherichia coli, they were separated by a 1100-bp region in Citrobacter
freundii (194). This region appeared to contain the regulatory element required for the
inducibility of AmpC (194). Indeed, when this 1100-bp region was cloned independently
from the ampC gene, it repressed the expression of ampC, suggesting that it encoded a trans
regulatory element (174). Using a minicell system, the small 1-kb region was also
demonstrated to express a 31-kDa protein, known as AmpR (174). Notably, as compared to
the absence of ampR, the presence of Citrobacter freundii ampR resulted in more than twofold increase in Citrobacter freundii AmpC β-lactamase activity in the presence of β-lactam
agents in Escherichia coli (174). This indicated that AmpR might have a dual role in βlactamase expression, as a repressor in the absence of an inducer, and as an activator in the
presence of the inducer (174).
Similar to Citrobacter freundii, in Enterobacter cloacae, the frd operon and ampC gene do
not overlap (194). Using a minicell system, Honore et al. and Lindberg et al. demonstrated
that the region between the frd operon and ampC gene encoded for a polypeptide of 31.5
kDa (175,195). Consistent with the nomenclature in Citrobacter freundii, this gene was
called the ampR. Under non-induced condition, Enterobacter cloacae ampC expression was
constitutively low in Escherichia coli, albeit the presence of ampR (195). This observation
suggested that unlike Citrobacter freundii AmpR, Enterobacter cloacae AmpR might not
act as a repressor of ampC in the absence of an inducer. The repressive function of
Citrobacter freundii AmpR was further confirmed using Citrobacter freundii ampC in an
Escherichia coli host, in which the synthesis of Citrobacter freundii AmpC β-lactamase was
eleven-fold lower in the presence of the homologous ampR gene than when complementing
with ampR from Enterobacter cloacae (195).
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However, the inductive role of Citrobacter freundii and Enterobacter cloacae ampR gene
product was indistinguishable because the Enterobacter cloacae AmpC β-lactamase was
elevated approximately 42-fold and 40-fold, respectively, when the Enterobacter cloacae or
Citrobacter freundii ampR was present in trans (195). So, though it is highly homologous,
Citrobacter freundii and Enterobacter cloacae AmpR exhibited different properties in the
regulation of cognate ampC gene.
The ampR gene encodes a DNA-binding protein that belongs to the LysR family of
regulatory proteins (196). The LysR family comprises of small sized, autoregulatory
transcriptional regulators. They have a helix-turn-helix motif at the N-terminus and
substrate-binding domain(s) at the C-terminus. The function of the DNA-binding motif
depends upon binding of the substrate-binding domain to small molecules as co-inducers or
co-repressors (196). Mutational studies and amino acid sequence similarities identify: (a) a
DNA-binding domain employing a helix-turn-helix motif (residues 1–65), (b) domains
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involved in co-inducer recognition and/or response (residues 100–173 and 196–206), (c) a
domain required for both DNA binding and co-inducer response (residues 227–253;(196)).
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Gel-mobility-shift assay is a common way to examine the interaction of a DNA-binding
molecule to a DNA fragment. Crude cellular extracts of Escherichia coli harboring the
Citrobacter freundii ampR in trans was demonstrated to retard the radioactively-labeled
ampR-ampC intercistronic region (197). No significant difference in mobility shift was
detected when extracts from the wild type Escherichia coli was used. This retardation in gel
mobility clearly indicated that the AmpR is a DNA-binding protein (197). It interacts
specifically with the ampR-ampC intercistronic region and thus regulates the expression of
ampC (197).
In order to the determine the DNA binding region more precisely, a more refined technique,
DNase I footprinting, is often used. DNase I footprinting using cellular extracts from
Escherichia coli expressing Citrobacter freundii ampR, a DNA segment of 38-bp was
indicated to bind to AmpR (197). This 38-bp region was located immediately upstream of
the ampC promoter. The addition of β-lactam antibiotics did not change the footprinting
properties of AmpR (197). However, a slight change the footprinting of Citrobacter freundii
AmpR with muramyl pentapeptide has been observed and discussed in detail below (198).
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The 38-bp AmpR binding site overlaps the AmpR promoter (197). This led to the
postulation that AmpR binding represses its own expression, an auto-regulatory mechanism
frequently seen with other LysR transcriptional factors (196). However, the auto-regulatory
mechanism of ampR was not consistent. In an in vivo system using an Escherichia coli
heterologous host, the PampR-lacZ activity was repressed three-fold in the presence of
Citrobacter freundii ampR. (174). However, this mode of regulation was lost in a minicell
system with Enterobacter cloacae AmpR (195). The latter concurred with studies of
Citrobacter freundii and Pseudomonas aeruginosa ampR: the amount of Citrobacter
freundii AmpR expressed in Escherichia coli minicells remains constant in the absence and
presence of inducer (174), constitutive ampR expression is low with a short half-life mRNA
(175), and that the ampR transcription (199), (197) and the level of AmpR remains
unaffected in the absence and presence of antibiotics (197).
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The sequence of the 5′-end of Pseudomonas aeruginosa ampR was initially reported along
with the ampC gene and subsequently, the whole sequence was described (163,200). Based
on the sequence analysis, the Pseudomonas aeruginosa ampR gene product was predicted to
be a polypeptide of 323 amino acids with a helix-turn-helix motif at the N-terminus (200).
By aligning sequences with those of Enterobacter cloacae and Citrobacter freundii, Lodge
et al. proposed that the translation initiation codon of the Pseudomonas aeruginosa ampR
was a rare TTG codon, rather than the usual ATG start codon (163). Overall, this rare TTG
codon accounts for only 1 % of the known initiator sequences (201). The derived amino acid
sequence showed a high degree of identity with Enterobacter cloacae AmpR (62.5 %) and
Citrobacter freundii AmpR (58.3 %; (200)). The binding motif of Citrobacter freundii
AmpR was also present in the ampR-ampC intercistronic region of Pseudomonas
aeruginosa (200). In a gel mobility-shift assay, crude cell extracts of Escherichia coli
containing the Pseudomonas aeruginosa ampR was shown to bind to the region ~50 bp
upstream of ampR, but not to the promoter region of ampC (200).
Recent work on Pseudomonas aeruginosa AmpR shows that it is a global regulator because
the strain carrying the ampR mutation produced higher levels of pyocyanin and LasA
protease, and lower levels of LasB elastase (199). The production of LasA protease has been
correlated with the LasI-LasR quoromone system (202,203). In the Pseudomonas
aeruginosa ampR mutant, the increase in LasA levels positively correlated with the lasI/R
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quorum sensing gene expression (199). The reduction in the LasB activity was positively
correlated with the rhlI/R quorum sensing gene expression. Thus, AmpR plays a dual role,
positively regulating ampC, lasB, and rhlR expression, and negatively regulating poxB, lasA,
lasI, and lasR expression (199).
ampD and ampE
When Escherichia coli K-12 harboring Citrobacter freundii ampR-ampC was grown with
high concentration of cefotaxime, chromosomal mutants producing high level of βlactamase constitutively arose at a considerable rate (10−6 to 10−7; (174). Analyses of these
mutants showed the presence of an intact functional ampC-ampR genetic region, and the
phenotype could not be complemented using a Citrobacter freundii frd-ampC region,
suggesting the presence of other regulatory genes (174). In addition, when the frd-ampC
region of a β-lactamase overproducing Enterobacter cloacae strain was transformed into
Escherichia coli, an inducible expression of AmpC β-lactamase was observed, ruling out
any loss of integrity of the frd-ampC region (204). These led to the hypothesis that the
constitutive β-lactamase overproduction was due to loss of function in a gene required for
inducibility that resided outside of ampR-ampC in the chromosome of Escherichia coli
(205). In addition, the constitutive overproduction of β-lactamase was lost in the absence of
ampR, suggesting that the function of the gene was ampR-dependent (174).
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The mapping of this novel mutation was a tedious task. Using a series of Tn10 transposon
mutageneses and Hfr strains, the mutation in Escherichia coli was localized to the nadC-lpd
region (205). An Escherichia coli strain with a deletion at nadC-aroP region also showed
constitutive production of Citrobacter freundii AmpC β-lactamase, suggesting that a gene
necessary for inducibility was located within this region (205). By supplementing the nadCaroP region in trans, the inducible β-lactamase phenotype could be restored from
Escherichia coli strains that overproduced the enzyme (205). Using a similar approach as
Lindberg et al. (205), Honore et al. identified that a loss of Escherichia coli nadC-aroP
region also caused an overproduction of Enterobacter cloacae AmpC (206).
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Dideoxy-sequencing of the nadC-aroP region of Escherichia coli revealed the presence of
two ORFs (206,207). The upstream ORF was designated ampD, overlapping the
downstream ampE. A S1 nuclease protection assay confirmed that the two ORFs constituted
an operon (206). Primer extension analysis performed on ampDE transcript showed that the
5′-end of the ampD mRNA was localized to an adenosine residue 29 nucleotides upstream
from the translational start codon (206). This knowledge of the transcript start site enabled
the promoter to be pinpointed. The promoter of the ampDE operon did not possess a
canonical -35 region, recognized by the σ70 RNA polymerase holoenzyme. The -10 region
(5′-TACTCT-3′) resembled the consensus sequence and was preceded by a TG motif at -12
(206). The TG motif has been reported to greatly strengthen promoters lacking the
consensus -35 element (208,209).
The Escherichia coli ampD gene product is 183 amino acids long with an apparent
molecular weight of 25 kDa. The Escherichia coli AmpE, with 284 amino acids, has its
putative initiation codon overlapping the ampD stop codon. Escherichia coli AmpE has an
apparent molecular weight of 28 kDa (207). Using a minicell fractionation technique, AmpD
was demonstrated to localize in the cytoplasm. This was in agreement with its hydopathy
profile that is indicative of a hydrophilic protein (207).
Fractionation of minicell harboring Escherichia coli ampE showed that AmpE was located
in the inner membrane fraction. The AmpE hydrophobicity plot suggested the presence of
four transmembrane regions: residues 44–60, 68–84, 195–211 and 268–284 (207). The
primary sequence of Escherichia coli AmpE possessed two of the three motifs found in βAPMIS. Author manuscript; available in PMC 2011 January 1.
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lactam binding proteins (210). These are the Ser-Arg-Asn corresponding to the Ser-X-Asn
motif, and the Ser-Met-Ala-Lys corresponding to the Ser-X-X-Lys motif (206). However,
Escherichia coli AmpE failed to bind to any β-lactam antibiotics (207). In addition, AmpE
could be an ATP-binding protein because the Walker’s ATP-binding consensus is found at
residues 74–87 and 184–198 (207). The function of AmpE in Escherichia coli is not clear,
however, unpublished data suggests that it plays a role in D-Ala D-Ala murein recycling
(40).
Phenotypically, the loss of Escherichia coli ampD caused a constitutive overproduction of
AmpC β-lactamase that could be further induced by the addition of an inducer, suggesting
that ampD acts as a negative regulator of ampC. This was in contrast to the loss of
Escherichia coli ampD and ampE that caused high level of β-lactamase production
constitutively, and the level could not be increased any further, albeit the addition of an
inducer (207). Moreover, the complementation of Escherichia coli ampE in an ampDE
mutant background restored only 50 % of the Enterobacter cloacae AmpC β-lactamase
induction (206). These data strongly suggest that ampE also played a role in the inducibility
of ampC. However, intriguingly, the inducible phenotype of the ampDE mutant could be
complemented with ampD alone (207). This could have been due to overproduction of
AmpD from a multicopy plasmid.
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At this point, it is noteworthy that all the extensive molecular studies were performed using
Escherichia coli ampD and ampE, which complemented the constitutive expression of
Citrobacter freundii and Enterobacter cloacae β-lactamases (205–207). Thus far, no
homologous system has been developed to understand the mechanism. Hence, little is
known about the Citrobacter freundii and Enterobacter cloacae ampDE genes, except for
the presence of ampDE homologs in these organisms (205,211). Sequencing of the wildtype ampD gene of Citrobacter freundii and Enterobacter cloacae revealed that they are 564
bp, corresponding to a gene product of 187 aminoacid long (212). Sequence comparison
revealed that they share 74 to 83 % homology to Escherichia coli ampD at the nucleotide
level (212). This level of homology is similar to those found for their respective ampC and
ampR genes, reflecting that these molecules evolved simultaneously (162,175,212). More
importantly, the three AmpD proteins are highly homologous except for their carboxyl
termini with a loss of four amino acids in Escherichia coli AmpD. As compared to
Escherichia coli, Enterobacter cloacae and Citrobacter freundii AmpD carry four additional
amino acids yielding a Ser-X-X-Lys motif typically found in β-lactamases and penicillinbinding proteins (210). However, AmpD is unlikely to belong to this family of proteins
because other signature motifs of β-lactam binding proteins are not present (212). To
determine the importance of the carboxyl terminus of Enterobacter cloacae AmpD, a stop
codon was introduced, giving rise to a truncated ampD gene product lacking the 16
carboxyl-terminal residues (212). Though the truncated AmpD protein is stable, the
truncated protein failed to complement the Escherichia coli ampD mutation, indicating that
the carboxyl terminus of Citrobacter freundii and Enterobacter cloacae AmpD was crucial
for its function (212). On the other hand, so far, the identity of Citrobacter freundii and
Entrobacter cloacae ampE remains unreported, however, our analysis of the sequenced
Citrobacter rodentium genome revealed the presence of an AmpE homolog.
Mutation of ampD gene caused an uncontrolled expression of AmpC β-lactamase, leading to
the hypothesis that AmpD was most likely a negative regulator of ampC transcription.
However, the primary protein structure of AmpD had no characteristic helix-turn-helix motif
or Zn-binding finger, two well-known DNA-binding motifs (206). So, it was postulated that
AmpD might not affect the transcription of ampC directly, but it might act through the
transcription factor AmpR since the constitutive expression required ampR (174). In
addition, it has been speculated that AmpD played a role in murein metabolism since
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Escherichia coli strains with defective ampD lost up to 40 % of their cell wall per generation
(213,214). The function of AmpD was elucidated when a highly purified functional AmpD
protein was incubated with Escherichia coli sacculi (215). The presence of AmpD decreased
the relative amount of all anhydromuropeptides, suggesting that AmpD was involved in the
metabolism of murein (215). Using a more refined isolate of muropeptides, AmpD was
shown to degrade anhydro-N-acetylmuramyl-L-Ala-D-Glu-DAP (anhMurNAc-tripeptide)
over time, giving rise to anhMurNAc and tripeptide (216). Hence, AmpD protein cleaved
the amide bond between the carboxyl group of anhydro muramic acid and the α-amino
group of L-Ala-D-Glu-DAP (216). AmpD appeared to be specifically cleaving the 1,6
anhydro bond on the muramic acid since MurNAc-pepides, and the cytoplasmic precursors
of murein, UDP-MurNAc-peptides, were not cleaved by AmpD (216). This unique 1,6
anhydro bond was the results from an intramolecular transglycosylation reaction that
occurred when the peptidoglycan was degraded by the periplasmic Escherichia coli lytic
transglycosylases (217). Murein precursors did not contain the 1,6 anhydro bond, allowing
AmpD to distinguish the precursors from the murein degraded products. This functional
specificity of AmpD was similar to the membrane-bound N-acetyl-anhydromuramyl-Lalanine amidase of Escherichia coli (218). However, instead of interacting with the
cytoplsmic membrane, AmpD is a cytosolic N-acetyl-anhydromuramyl-L-alanine amidase
(216).
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Besides Citrobacter freundii, Escherichia coli and Enterobacter cloacae, the ampDE region
had also been determined in Pseudomonas aeruginosa. The Pseudomonas aeruginosa
ampDE region was detected using a degenerate probe against a phage genomic library of
PAO1 (219). This strategy located ampD gene to a 2.6-kb genomic region. Sequencing of
this 2.6-kb DNA fragment revealed two ORFs (219). The Pseudomonas aeruginosa ampD
gene was 567-bp long, corresponding to a gene product of 188 amino acids with a predicted
molecular mass of 21 kDa. The deduced Pseudomonas aeruginosa AmpD protein exhibited
65, 63 and 62 % similarity to the Escherichia coli, Citrobacter freundii and Enterobacter
cloacae AmpD proteins, respectively (219). However, our analysis shows that although the
carboxyl terminus of Citrobacter freundii, E. cloacace and Pseudomonas aeruginosa AmpD
proteins are highly conserved, the Ser-X-X-Lys motif found at the carboxyl terminus of
Citrobacter freundii and Enterobacter cloacae was not found in Pseudomonas aeruginosa
AmpD.
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Similar to the gene organization in Escherichia coli, the Pseudomonas aeruginosa ampE
start codon overlapped the translational termination codon of ampD. Pseudomonas
aeruginosa ampE encoded a 278-aminoacid polypeptide with predicted molecular weight of
31 kDa (219). The predicted Pseudomonas aeruginosa AmpE gene product had the
characteristic of a cytoplasmic membrane protein with five predicted transmembrane
domains. However, it showed a relatively low degree of homology (33 %) to the counterpart
in Escherichia coli (219).
In spite of the sequence, virtually nothing is known about the molecular biology of
Pseudomonas aeruginosa ampDE. Similar to Escherichia coli, Pseudomonas aeruginosa
ampDE was believed to form an operon and transcript simultaneously. Unfortunately,
without accompanying primer extension analysis or any techniques to determine the 5′-end
of the ampDE transcript, Langaee et al. claimed that the putative -10 and -35 promoter
consensus were 14 and 36 bp, respectively, upstream of a putative Shine-Dalgarno sequence
of ampD (219). However, without any conventional techniques, the authentic promoter of
Pseudomonas aeruginosa ampDE remains elusive. In addition, our analysis shows the
absence of any strong ρ-independent terminator at the 3′-end of ampE, suggesting that the
termination of the transcript may be ρ-dependent.

APMIS. Author manuscript; available in PMC 2011 January 1.

Kong et al.

Page 22

NIH-PA Author Manuscript

To determine the function of Pseudomonas aeruginosa ampD and ampE gene product, two
Escherichia coli strains, ampD and ampDE mutants, harboring Enterobacter cloacae ampRampC genes in trans were used for complementation analysis (219). In a heterologous
system using components from three bacterial species, Pseudomonas aeruginosa ampD
alone and ampDE were exhibited to restore the wild-type expression of Enterobacter
cloacae AmpC β-lactamase, low basal level and inducible expression in the presence of βlactam antibiotics, in the Escherichia coli background regardless of nature of the mutations
(219). However, the β-lactamase induction was reduced two-fold and 1.5-fold in the
presence of Pseudomonas aeruginosa ampE, as compared to the absence of ampE and
Escherichia coli ampE, respectively (219).
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In a subsequent analysis of Pseudomonas aeruginosa ampDE, a polar gentamycin cassette
was inserted within the ampD gene, generating an isogenic Pseudomonas aeruginosa
ampDE mutant, notwithstanding the author’s claim that it was an ampD-defective strain
(220). The ampDE mutation of Pseudomonas aeruginosa led to six- and 32-fold increases in
the minimum inhibitory concentration (MIC) of ampicillin and cefotaxime, respectively, as
well as a 37-fold elevation of the basal non-induced β-lactamase level (220). Unlike
Escherichia coli where the loss of both ampD and ampE caused a non-inducible high level
of β-lactamase synthesis (207), the β-lactamase production of Pseudomonas aeruginosa
ampDE mutant was induced 22-fold in the presence of an inducer (220). This discrepancy
suggested that Pseudomonas aeruginosa ampD and/or ampE might play a different role than
those of Escherichia coli. However, no complementation analysis was done to confirm their
finding (220). Some of these discrepancies could be explained by the recent realization that
Pseudomonas aeruginosa encodes three ampD homologs, ampD, ampDh1, and ampDh2,
and these are responsible for step-wise upregulationof β-lactamase expression (221).
Although single or double mutants of the ampD homologs do not affect Pseudomonas
aeruginosa fitness in vitro, deletion of all three genes does (222). This cost of fitness is due
to upregulation of ampC because ampC deletion restores fitness (222). Interestingly, in a
mouse model, ampD ampDh2 or ampD ampDh3 double mutants as well as the triple mutant
affect fitness. This effect of the triple mutant is ampC independent. Of the three, ampDh3
plays the greatest role in virulence in a mouse model system; an ampD ampDh2 double
mutant also has reduced virulence (222). This study also looked at the ampD homologue
sequences of β-lactamase wild type and overproducing pairs of clinical isolates from ten
different subjects (222). Although six of the overproducing strains contained mutations in
ampD, loss of function mutations were not identified in ampDh2 or ampDh3, consistent with
a high biological fitness cost of the double mutants (222). These findings also suggest that
the four groups of β-lactamase producers identified by Campbell et al (189) may harbor
mutations in the various ampD genes.
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ampG
In comparison to other amp genes, the ampG gene was the least characterized. The ampG
was discovered when an Enterobacter cloacae strain 55M-L was reported to produce
constitutive low-levels of β-lactamase (223). This intriguing strain was derived from an
ampD parental strain, Enterobacter cloacae 55M, which synthesized a high basal level of βlactamase constitutively (223). Complementation analyses with wild-type ampR-ampC and
ampD failed to recover the parental phenotype (224). Furthermore, the 55M-L ampR-ampC
and ampD regions retained the activities of the parental strain, suggesting that a novel locus,
known as ampG, which was unlinked to ampR-ampC or ampD, was responsible for the lowbasal β-lactamase level (224). Based on the assumption that low-level constitutive
expression of β-lactamase in Enterobacter cloacae was due to a novel mutation in ampG, it
was proposed that a wild-type ampG allele of the gene should be dominant over the mutated
allele (224). If this was correct, the introduction of the wild-type ampG allele should change
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Enterobacter cloacae 55M-L into a resistant strain since it was mutated in the ampD gene
(224). A random genomic library was constructed using a wild-type Enterobacter cloacae
chromosome and transformed into Enterobacter cloacae strain55M-L. Selection of the
resistant transformants showed that a 2.9-kb fragment was able to transform Enterobacter
cloacae 55M-L into a β-lactam resistant strain that produced β-lactamase as high as the
parental strain, 55M (224). The presence of this 2.9-kb fragment along with the ampD gene
in Enterobacter cloacae M55 re-established the inducibility of the AmpC β-lactamase (224).
Since a mutation in ampG led to an effect that was dominant over the phenotypes of ampR
and ampD, it was proposed that AmpG might play a role upstream of AmpR and AmpD in
the induction of AmpC β-lactamase (224).
The presence of an ampG locus in Escherichia coli was confirmed through Southern blotting
using the Enterobacter cloacae 2.9-kb ampG fragment (225). A 3.2-kb fragment containing
ampG from Escherichia coli was able to complement Enterobacter cloacae 55M-L (225).
An ampG knockout mutant was generated in Escherichia coli using allelic replacement via
homologous recombination (225). The resulting ampG mutant was unable to induce
Citrobacter freundii AmpC β-lactamase in the presence of an inducer, confirming that the
induction of Citrobacter freundii AmpC required a functional ampG gene (225).
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Sequencing of the Escherichia coli 3.2-kb fragment showed the presence of two ORFs
flanked by an upstream bloA gene and a downstream cyoA gene, which encoded a
morphogene that affected carboxypeptidase activity, and the cytochrome o ubiquinol
oxidase, respectively (225). The deduced AmpG protein sequence yielded a 491 amino acid
polypeptide with a predicted molecular mass of 53.2 kDa. However, minicells carrying
Escherichia coli ampG could not detect the presence of AmpG in the cytoplasmic fraction
(225). Bioinformatic analysis and fusion analysis suggested the existence of 10 membranespanning regions in the ampG gene product (225,226).
Upstream of ampG, there was an ORF of 579-bp in the same orientation. This preceding
ORF might encode a putative lipoprotein since it contains a strong lipoprotein signal of LeuX-Gly-Cys (225). A polar insertional inactivation of this ORF showed a non-inducible
phenotype of Escherichia coli harboring Citrobacter freundii ampR-ampC, similar to an
ampG mutant (225). But, the β-lactamase inducibility was regained when the strain was
complemented with ampG alone or orf-ampG, suggesting that the lipoprotein played no role
in β-lactamase induction (225).
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When the Escherichia coli ampG gene was cloned with the upstream intergenic region, a
promoter must be inserted upstream in order to complement a chromosomal ampG mutation.
This strongly suggested that the ampG promoter was not immediately upstream (225).
Furthermore, the short 43-bp intracistronic sequence did not contain any Escherichia coliσ70
promoter consensus, suggesting that ampG was co-transcribed with an upstream ORF of 495
bp (225). A northern blotting analysis using an ampG probe showed a band of 2.4 kb
corresponding to the transcript size covering both the ampG and ORF, confirming the
hypothesis that ampG and its upstream ORF constituted an operon (225). Using primer
extension analysis, the 5′-end of the transcript was mapped to a G residue, 43 bp upstream of
the proposed AUG start codon of the upstream ORF (225). With this information in hand,
the determined promoter of the ampG operon showed high homology to the consensus
sequence for RpoD promoters (225).
However, interestingly, when a probe hybridizing to the upstream ORF was used in the
northern blot, two transcripts of 0.7-kb and 2.4-kb in size were found (225). The 2.4-kb band
corresponded to the transcript of both the ampG and the upstream ORF, whereas the 0.7-kb
transcript coincided with the expected size of the upstream ORF alone (225). This suggests
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that although the two genes were transcribed in an operonic manner, expression of
Escherichia coli ampG was post-transcriptionally regulated. Examination of the intergenic
region between the ORF and ampG revealed the presence of a short inverted repeat of 11 bp
upstream of the start codon of ampG (225). This inverted repeat was believed to function as
a transcriptional terminator. In order to further determine the regulation of the ampG gene,
two promoter fusions, Porf-lacZ and PampG-lacZ, were constructed (225). It was indicated
that the β-galactosidase activity of Porf-lacZ was always 1.5-fold higher than the
transcription of PampG-lacZ, confirming the northern blot data that there was down
regulation of ampG transcription (225). However, the ampG transcription was not affected
by AmpD or different growth phases (225).
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Although AmpG protein appeared to be a transmembrane protein, the function of AmpG
remains elusive. The fact that Escherichia coli contains ampG and ampD genes, even though
this organism lacks the ampR gene and an inducible ampC gene, provided clues that the
primary functions of AmpG and AmpD proteins were not involved in AmpC β-lactamase
induction (175,205,225). The initial clue of AmpG function came from Jacobs et al., who
demonstrated that Escherichia coli strains with a defective ampG gene lost 20–40 % of the
labeled muropeptides from their cell wall in each generation, whereas the control strain lost
only 4–8 % per generation (213). In addition, a large proportion of the labeled muropeptides
was released into the medium (213). These data indicated that Escherichia coli strains with a
defective ampG gene were unable to reuse the cell wall components during cell
regeneration. This data together with the fact that AmpG was a transmembrane protein
suggest that AmpG protein acted as a permease that allowed the transport of peptidoglycan
recycling intermediates from the bacterial periplasm to the cytoplasm (213).
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To ascertain the specific function of AmpG, hot water extracts of the DAP-labeled wild-type
Escherichia coli and a Escherichia coli strain with defective ampG were analyzed using
high pressure liquid chromatography (HPLC) (213). It was demonstrated that the ampG
mutant failed to retain anhMurNAc-peptides in the cytoplasm. However, the presence of
anhMurNAc-peptides, the AmpD substrates, remained peculiar because the unprocessed
enzymatic products of cell wall hydrolyases were GlcNAc-anhMurNAc-peptides (213).
Thus, the ampG gene product could be transporting either the GlcNAc-anhMurNAcpeptides or anhMurNAc-peptides into the cytoplasm. To determine whether GlcNAcanhMurNAc-peptides were cleaved in the periplasm or cytoplasm, the culture medium of the
ampG mutant was assayed. A large amount of GlcNAc-anhMurNAc-peptides was found in
the culture medium of Escherichia coli ampG and not in the wild-type, suggesting that
AmpG protein was a transporter of GlcNAc-anhMurNAc-peptides from the periplasm to the
cytoplasm (213). The GlcNAc-anhMurNAc-peptides were then cleaved in the cytoplasm by
an intracellular N-acteyl-glucosaminidase (227,228).
In a different experiment, the substrate specificity of AmpG was investigated (229). Using
different GlcNAc-anhMurNAc-peptides of various lengths, it was shown that the principal
requirement of AmpG was the presence of GlcNAc-anhMurNAc disaccharide, independent
of the length of the peptide side chain (229). Muropeptides lacking either GlcNAc or
anhMurNAc were not imported into the cytosol. In addition, the function of AmpG was
sensitive to carbonyl cyanide m-chlorophenylhydrazone (CCCP), an H+ ionophore that
dissipates the H+ gradient and uncouples electron transport from ATP synthesis (230),
suggesting that AmpG transport is dependent on the proton motive force.
Although the ampG gene was first detected in Enterobacter cloacae (224), all the molecular
and biochemical work were performed on the Escherichia coli ampG gene and its gene
product (213,225). The ampG homolog of Enterobacter cloacae remains to be
characterized. Analysis of sequenced Pseudomonas aeruginosa PAO1 genome shows the
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presence of two copies of ampG, currently designated as ampG and ampP (Kong et al.
manuscript submitted). Both the permeases are essential for β-lactamase induction.
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MUREIN RECYCLING AND β-LACTAMASE INDUCTION
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The most important issue in the study of β-lactamase induction is the coordinate regulation
of the presence of β-lactam antibiotics in the periplasm, and the intracellular activation of βlactamase. β-lactam antibiotics are known to act on the murein localized in the periplasm,
thus these chemicals do not enter the cytoplasm to mediate their effects. Yet, the presence of
β-lactam agents is able to induce β-lactamase, suggesting that an efficient communication
must exist between the extracellular site of β-lactam actions and the intracellular site of βlactamase transcription. Because of structural homology between β-lactam ring and Dalanyl-D-alanine, Tuomanen et al. proposed that the pathway that leads to the induction of
β-lactamase expression may share regulatory components with the pathway of cell wall
metabolism (214). If this is true, the authors postulated that mutants with altered β-lactamase
induction must have aberrant cell wall metabolism. To test the hypothesis, the difference in
peptidoglycan composition between wild-type Escherichia coli and an isogenic mutant with
defective ampDE was determined using HPLC (214). Interestingly, it was shown that the
muropeptide composition in ampDE mutant was profoundly altered as compared to the
wild-type. However, this alteration could be recovered by complementing the ampD alone in
trans, suggesting that ampE played a subtle role in this event (214). Thus, it is proposed that
the ampD gene product repressed the β-lactamase activity by retaining the concentration of
GlcMurNAc-L-Ala-D-Glu-meso-DAP-D-Ala-D-Ala (214). Two important phenomena
converged in this study: murein recycling and β-lactamase induction.
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The current molecular model of β-lactamase induction was proposed (Fig. 6). According to
this model, during cell growth, specific cell wall hydrolyases degrade the peptidoglycan to
yield murein-peptides with different lengths. This muropeptides (Glc-anhMurNAc-peptides)
are transported into the cytoplasm by the permease AmpG. They are then directly cleaved by
AmpD, an N-acetylmuramyl amidase, into the N-acetylmuramic acids and peptides (Fig. 6).
During normal physiologic growth, ampC expression is repressed by AmpR binding to the
promoter region (Fig. 6; (198)). Jacobs et al. demonstrated that in the presence of β-lactam
antibiotics, there was a relative decrease in the murein precursors, UDP-MurNAc-L-Ala-DGlu-meso-DAP-Ala-Ala (213). It was postulated that the Citrobacter freundii AmpR was
maintained in the repressive form by the murein precursors. This was indeed demonstrated
with purified AmpR in an in vitro transcription assay that the ampC transcript diminished
with an increase of UDP-MurNAc-pentapeptide (198). In addition, the negative effect of
UDP-MurNAc-pentapeptide in β-lactamase induction was also investigated by using an
AmpR mutant, AmpRGly102Glu (198). Expression of this AmpR variant resulted in a high
basal-level constitutive β-lactamase expression in the absence of β-lactam agents in wildtype as well as in an ampG mutant (231). In the transcription assay, purified AmpRGly102Glu
behaved like the wild-type protein in the activation of ampC transcription. However,
increasing concentrations of UDP-MurNAc-pentapeptide failed to reduce the level of
AmpRGly102Glu-mediated ampC transcription (198). This result clearly indicated that an
UDP-MurNAc-pentapeptide binding-site was present in AmpR around amino acid 102.
On the other hand, gel mobility-shift assay showed no difference in the DNA binding
property between the wild-type AmpR and AmpRGly102Glu (198). Detailed study carried out
using DNaseI footprinting also gave rise to an identical footprint (198). However, the
presence of UDP-MurNAc-pentapeptide resulted in a small but consistent alteration in the
protection pattern of wild-type AmpR, but not AmpRGly102Glu (198). Specifically, the base
in position -49 (relative to the +1 site of ampC) was not protected by the wild-type AmpR in

APMIS. Author manuscript; available in PMC 2011 January 1.

Kong et al.

Page 26

the presence of UDP-MurNAc-pentapeptide, though the significance of this nucleotide was
not discussed (198).
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The identification of a repressing ligand of AmpR was not sufficient to explain the induction
of ampC transcription because the increased pool of UDP-MurNAc-pentapeptide in an
ampD mutant exhibited a high basal-level of β-lactamase expression constitutively (213). It
was then proposed that a different ligand may be responsible for the co-induction of ampC
transcription. In this case, anhMurNAc-tripeptide served as a potential candidate since it
dramatically accumulated in an ampD mutant (213). In an in vitro transcription experiment,
anhMurNAc-tripeptide consistently exerted the negative effect of UDP-MurNAcpentapeptide on ampC transcription (198). Thus, in the presence of β-lactam antibiotics, as a
result of increased murein breakdown, high concentration of anhMurNAc-tripeptide
displaced the repressing UDP-MurNAc-pentapeptide from its AmpR-binding site (Fig. 5;
(198)). However, it was not known if the footprint of AmpR changed with the binding to
anhMurNAc-tripeptide.
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The delicate coordination of murein breakdown and β-lactamase expression was elegantly
demonstrated using a complicated heterologous system (Fig. 5; (198)). Most of the
experiments were performed in an Escherichia coli background which carried Citrobacter
freundii or Enterobacter cloacae ampR-ampC system. Escherichia coli does not have an
inducible AmpC β-lactamase, albeit the presence of ampD and ampG. The Escherichia coli
ampC was regulated through an attenuator present at the 5′-end of the ampC transcript (182).
β-lactam resistance in Escherichia coli clinical isolates was brought upon by various
mechanisms, including tandem amplification of the ampC gene caused by recombination
between short homologies (232), mutations to the promoter region that up-regulated ampC
expression (233), insertion of an IS element at the promoter that created a strong σ70
promoter (234), and horizontal chromosomal DNA transfer from Shigella (235). Thus far,
no data has demonstrated the importance of Escherichia coli ampD and ampG in the
transcriptional up-regulation of its cognate ampC. Moreover, Citrobacter freundii and
Enterobacter cloacae ampD and ampG have not been sufficiently demonstrated to involve
AmpC β-lactamase induction or cell wall metabolism in a homologous system. The
Citrobacter freundii ampR gene product is believed to bind to different murein breakdown
products and murien precursors present in Escherichia coli. The identity and the
physiological concentration of these molecules in Citrobacter freundii, Enterobacter
cloacae, Pseudomonas aeruginosa or any other organisms remain to be defined.

CLOSING REMARKS
NIH-PA Author Manuscript

It is conceivable that the recognition of antibiotics marks one of the most important
milestones in human history. The use of antibiotics has brought upon immeasurable benefits
to medicine, physiology, and biology. Over the decades, the understanding of antibiotics and
the resistance to them has facilitated a deeper understanding of the microbial physiology and
pathogenesis. In addition, we have also exploited this knowledge as tools to facilitate the
search for new knowledge. For example, the ampicillin resistance gene is routinely used as a
selectable marker in recombinant DNA technology. However, as a community, we should
also proceed with caution because the misuse and abuse of these substances will lead to
unwanted consequences including the return of multi-drug resistant bacteria.
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6-APA

6-aminopenicillanic acid

7-ACA

7-aminocephalospoinic acid

anhMurNAc

anhydro-N-acetylmuramyl

ASM

American Society of Microbiology

ATP

adenosine triphosphate

CARB

Carbenicillin β-lactamase

CCCP

carbonyl cyanide m-chlorophenylhydrazone

DAP

diaminopimelic acid

DNA

deoxyribonucleic acid

EDTA

ethylenediaminetetraacetic acid

ESBL

extended spectrum β-lactamase

frd

fumerate reductase operon

GlcNAc

N-acetylglucosamine

HPLC

High performance liquid chromatography

kb

kilobase

kDa

kiloDalton

MIC

minimum inhibitory concentration

MurNAc

N-acetylmuramic acid

NIAID

National Institutes of Allergy and Infectious Diseases

ORF

open reading frame

PampR

ampR promoter

PBC

penicillin binding component

PBP

penicillin binding protein

PEP

phosphoenolpyruvic acid

PSE

Pseudomonas-specific β-lactamase

SDS-PAGE

sodium dodecyl sulfate-polyacrylamide gel electrophoresis

UDP-GlcNAc

Uridine diphosphate-N- acetylglucosamine

UDP-MurNAc

Uridine diphosphate-N-acetylmuramic acid
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Fig. 1.

Antibiotic hall of fame. Courtesy of Nobel e-Museum
(http://www.nobel.se/medicine/laureates/1945/index.html).
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Fig. 2.

Molecular structure of 6-aminopenicillic acid, 7-aminopenicillic acid and D-alanine Dalanine
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Fig. 3.
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Schematic representation of the (A) S. aureus and (B) Escherichia coli murein monomers.
(A) In S. aureus, N-acetylglucosamine and N-acetylmuramic acid form the backbone of the
murein. It is attached to pentapeptides containing L-alanine, D-glutamc acid, L-lysine and
D-alanyl-D-alanine. The two pentapeptides are linked with a penta-glycine cross bridge. (B)
In Escherichia coli, the murein backbone is composed of the same sugar moieties as S.
aureus, N-acetylglucosamine and N-acetylmuramic acid. The backbone is attached to
pentapeptides containing L-alanine, D-glutamic acid, L-diaminopimelic acid and D-alanylD-alanine. Cross-linking occurs between diaminopimelic acid and D-alanine. The Dalanines in red boxes are usually liberated upon transpeptidation.
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Fig. 4.
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The biosynthetic pathway of bacterial murein. The pathway initiates with committing steps,
generating UDP-acetylmuramic acid (UDP-MurNAc). L-alanine, D-glutamic acid, lysine or
diaminophenolic acid, and D-alanyl-D-alanine are enzymatically added to UDP-MurNAc in
a stepwise manner. The formation of UDP-acetylmuramyl-pentapeptide (UDP-MurNAcpentapeptide) occurs in the cytoplasm. Then, the UDP-MurNAc-pentapeptide is transferred
to the cytoplasmic membrane where two lipid carriers (Lipid I and Lipid II) are involved in
the joining of UDP-MurNAc-pentapeptide and UDP-acetylglucosamine (UDP-GlcNAc) to
form a linear murein with protruding short peptide chains. Finally, the linear murein chains
are cross-linked with each other and to pre-existing murein. A few chemical compounds are
known to block this pathway. β-lactams are known to inhibit the cross-linking, whereas
bacitracin inhibits the recycling of undecaprenyl. Moenomycin and vancomycin inhibit the
function of Lipid II that carries the disaccharide peptide monomer units.
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Fig. 5.

Structure of the active site of DD-carboxypeptidase and β-lactamase. A. The X-ray crystal
structure of E. coli PBP5 (240) and Bacillus licheniformis BS3 beta-lactamase (241). The
conserved SerXXLys, Ser[Tyr]XAsn, and Lys[His]Thr[Ser]Gly motifs (242) are colored in
yellow, orange and green, respectively. The catalytic serine of the SerXXLys motif is
colored in red.
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Fig. 6.
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Mechanism of β-lactamase induction in Enterobacteriaceae. In the absence of β-lactam
antibiotics, the murein is constantly being re-modeled for cell elongation and cell division.
The breakdown products, muramyl peptides, are released into the periplasm and transported
to the cytoplasm via AmpG. These muramyl peptides are then processed by ampD for the
murein recycling. In this instance, the ampC gene is kept at basal-level by a suppressed
AmpR transcriptional regulator. In the presence of β-lactam antibiotics, the homeostasis is
disrupted because these antibiotics target the murein resulting in an excessive breakdown of
the murein and an accumulation of the muramyl peptides both in the periplasm and
cytoplasm. However, the AmpD protein is the limiting factor. An accumulation of the
muramyl peptides renders the activation of AmpR, which then induces the production of
AmpC β-lactamase. It is not clear which of the muramyl products directly interact with
AmpR. AmpE has been implicated in the transport of free pentapeptide to the periplasm
(40). The transport of the muramyl peptides into the periplasm may involve AmpE or some
yet to be unidentified protein. Abbreviations, CM, IM, PP, PG and OM refer to cytoplasm,
inner membrane, periplasm, peptidoglycan and outer membrane, respectively.
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Table 1

The chemical composition of Gram-positive and Gram-negative bacterial murein.
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Gram positive

Gram negative

Glucosamine

Glucosamine

Acetylmuramic

Acetylmuramic

Sugar

Amino acid

D-Glutamic acid

D-Glutamic acid

D- and L-Alanine

D- and L-Alanine

L-Lysine or L- Diaminopimelic acid Glycine

L-Diaminopimelic acid
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Table 2

List of genes involved in cell wall biogenesis
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Proteins

Genes in E.
colia

Genes in P.
aeruginosab

Functional Annotation

Penicilin Binding Proteins

NIH-PA Author Manuscript

PBP1a

ponA/mrcA

PA5045

Membrane carboxypeptidase; Catalyzes the polymerization of the glycan subunit and
crosslinking of muropeptides

PBP1b

ponB/mrcB

PA4700

Membrane carboxypeptidase

PBP1c

pbpC

PA0378

Transglycosylase

PBP2

pbpA/mrdA

PA4003

Chain-length regulation; Murein-elongation initiating enzyme

PBP3

ftsI/pbpB

PA4418

Transpeptidation of muropeptides exclusively for septal murein synthesis; septal mureinsynthesizing enzyme; Important for cell dividion

PBP3a

None

PA2272

Transpeptidase

PBP4

dacB

PA3047

D-alanyl-D-alanine endopepidase

PBP5

dacA

PA3999?

D-alanyl-D-alaninecarboxypeptidase

PBP6

dacC

D-alanyl-D-alanine carboxypeptidase; Stabilization of the murein at the stationary phase

PBP6b

dacD

D-alanyl-D-alanine carboxypeptidase

PBP7/8

pbpG

PA0869

D-alanyl-D-alanine carboxypeptidase;

Other proteins involved in bacterial cell shape
EnvA

envA/asmB/lpxC

PA4406

UDP-3-O-acyl-N-acetylglucosamine deacetylase

RodA

rodA/mrdB

PA4002

Rod shape-determining protein

RodX

rodX

None

RodY/MreB/EnvB

rodY/mreB/envB

PA4481

Rod shape-determining protein

MreC

mreC

PA4480

Rod shape-determining protein

MreD

mreD

PA4479

Rod shape-determining protein

Other proteins involved in bacterial cell wall metabolism
MpaA

mpaA

None

Gamma-D-glutamyl-meso-diaminopimelate hydrolase

MtgA

mtgA (mgt)

PA0378

Glycan strand polymerization

Mpl

mpl

PA4020

UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase
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SltY

sltY

PA3020?

Lytic transglycosylase

MltA

mltA

PA1222

Lytic transglycosylase

MltB

mltB

PA4444/mltB1/sltB
PA4001/sltB1/mltB2

Membrane-bound lytic murein transglycosylase B
Lytic transglycosylase

MltC

mltC

PA3020?

Lytic transglycosylase

MltD

mltD

PA1812

Lytic transglycosylase

MltE

mltE/emtA

PA3764

Lytic transglycosylase

AmiA

amiA

PA5538

N-acetylmuramoyl-L-alanine amidase; Cell separation

AmiB

amiB

PA4947

Cell separationN-acetylmuramoyl-L-alanine amidase; Cell separation

AmiC

amiC

PA4947?/PA5538?

Cell separation

MepA

mepA

None

LD-endopeptidase

NagZ

nagZ

PA3005

β-N-acetyl-D-glucosaminidase

LdcA

ldcA

PA5198

LD-carboxypeptidase
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Proteins

Genes in E.
colia

Genes in P.
aeruginosab

Functional Annotation

EnvC

envC

PA5133

Endopeptidase

FlgJ

flgJ

PA1085

Muramidase (flagellum-specific)

AmpC

ampC

PA4110

AmpC beta-lactamase

AmpR

None

PA4109

Transcriptional regulator AmpR

Amp and Pox proteins

AmpD
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ampD

PA4522

1,6-anhydro-N-acetylmuramyl-L-alanine amidase

ampDh2

PA5485

N-acetyl glucosamidase

ampDh3

PA0807

N-acetyl glucosamidase

AmpE

ampE

PA4521

Hypothetical membrane protein

AmpG

ampG

PA4218

Transport of degraded muropeptides: GlcNAc- anhMurNAc

AmpF

None

PA4219

Hypothetical membrane protein

AmpP

None

PA4393

Permease

AmpO

None

PA4219

Hypothetical membrane protein

PoxA

None

PA5513

Hypothetical hydrolase

PoxB

None

PA5514

Class D beta-lactamase

murA

PA4450

UDP-N-acetylglucosamine enolpyruvyl transferase

MurB

murB

PA2977

UDP-N-acetylpyruvoylglucosamine reductase

MurC

murC

PA4411

UDP-N-acetylmuramate--alanine ligase

MurD

murD

PA4414

UDP-N-acetylmuramoylalanine--D-glutamate ligase

MurE

murE

PA4417

UDP-N-acetylmuramoylalanyl-D-glutamate-2, 6-diaminopimelate ligase

Mur & Mra proteins
MurA

MurF

murF

PA4416

UDP-N-acetylmuramoylalanyl-D-glutamyl-2, 6-diaminopimelate--D-alanyl-D-alanyl ligase

MurG

murG

PA4412

UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphorylundecaprenol N- acetylglucosamine transferase

MurI

murI

PA4662

Glutamate racemase

MraY

mraY

PA4415

Phospho-N-acetylmuramoyl-pentapeptide-transferase

MraW

mraW

PA4420

Peptidoglycan biosynthetic process with methyl transferase activity

MraZ

mraZ

PA4421

Role in cell-wall biosynthesis

MraR

mraR/ftsL

None

Cell division
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Information compiled from the EcoCyc, PseudoCyc and Pseudomonas databases (236–239)
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